Skip to main content
Bafna Pharmaceuticals Limited logo

Bafna Pharmaceuticals Limited — Investor Relations & Filings

Ticker · BAFNAPH ISIN · INE878I01022 LEI · 984500D03E2C7Y5EE587 BSE.NS Manufacturing
Filings indexed 249 across all filing types
Latest filing 2023-04-04 Board/Management Inform…
Country IN India
Listing BSE.NS BAFNAPH

About Bafna Pharmaceuticals Limited

http://bafnapharma.com/

Bafna Pharmaceuticals Limited specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities certified by WHO-GMP standards, ensuring high-quality production of finished dosage forms including tablets, capsules, syrups, and suspensions. Its therapeutic portfolio spans multiple categories such as anti-infectives, analgesics, cardiovascular, gastrointestinal, and vitamins. The organization serves both domestic and international markets, with a significant presence in emerging regions across Africa, Southeast Asia, and the CIS. In addition to its proprietary product line, the company provides comprehensive contract manufacturing and formulation development services, leveraging its technical expertise and regulatory compliance to meet global healthcare requirements.

Recent filings

Filing Released Lang Actions
Board Meeting — Other business matters
Board/Management Information Classification · 95% confidence The document is a short notice dated April 4, 2023, addressed to stock exchanges about a scheduled Board of Directors meeting on April 7, 2023. The purpose is to consider the appointment of a Company Secretary & Compliance Officer and other business. There are no financial statements, detailed reports, or regulatory filings included. The document is essentially an announcement of a board meeting, not the meeting materials or minutes themselves. Given the content and length (1581 characters), it fits the category of Board/Management Information (MANG), which covers announcements of changes or meetings related to the company's board or senior management.
2023-04-04 English
Financial Result Updates
Regulatory Filings
2023-02-09 English
Outcome of Board Meeting
Regulatory Filings
2023-02-08 English
Board Meeting — Financial Results
Regulatory Filings Classification · 100% confidence The document text is extremely short (96 characters) and contains only a digital signature with a date. There is no substantive content, financial data, or report information. It does not contain any report or announcement text. Given the lack of content, this is likely a regulatory filing or a minimal attestation document. According to the rules, such minimal content without report data defaults to Regulatory Filings (RNS).
2023-02-01 English
Updates
Regulatory Filings Classification · 90% confidence The document is extremely short (388 characters) and contains only digital signature information without any substantive content such as financial data, report details, or announcements. There is no indication of a report, announcement, or any specific filing type. Given the lack of content and the presence of a digital signature, this document most closely aligns with a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2023-01-20 English
Resignation
Regulatory Filings Classification · 95% confidence The document text is extremely short (261 characters) and contains only a digital signature and omitted pictures, with no substantive content or financial data. There is no indication of a full report, announcement, or detailed information. Given the brevity and nature of the content, it does not qualify as any detailed report or announcement. It is best classified as a Regulatory Filing (RNS), which serves as a fallback for miscellaneous filings that do not fit other categories.
2023-01-20 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.